［1］ HE L,VASILIOU K,NEBERT DW.Analysis and update of the human solute carrier (SLC) gene superfamily［J］.Hum Genomics,2009,3(2):195-206.
［2］ HEDIGER MA,CLEMENCON B,BURRIER RE,et al.The ABCs of membrane transporters in health and disease(SLC series):introduction［J］.Mol Aspects Med,2013,34(2-3):95-107.
［3］ COLAS C,UNG PM,SCHLESSINGER A.SLC transporters:Structure,function,and drug discovery［J］.MedChemComm,2016,7(6):1069-1081.
［4］ POCHINI L,GALLUCCIO M.Heterologous (over) expression of human solute carrier (SLC) in yeast:A well-recognized tool for human transporter function/structure studies［J］.Life (Basel),2022,12(8):1206.
［5］ RIVES ML,JAVITCH JA,WICKENDEN AD.Potentiating SLC transporter activity:Emerging drug discovery opportunities［J］.Biochem Pharmacol,2017,135:1-11.
［6］ GYIMESI G,HEDIGER MA.Sequence features of mitochondrial transporter protein families［J］.Biomolecules,2020,10(12):1611.
［7］ ZORATTI M,BIASUTTO L,PARRASIA S,et al.Mitochondrial permeability transition pore:a snapshot of a therapeutic target［J］.Expert Opin Ther Targets,2024，28(1-2):1-3.
［8］ KUNJI ERS,KING MS,RUPRECHT JJ,et al.The slc25 carrier family:Important transport proteins in mitochondrial physiology and pathology［J］.Physiology(Bethesda),2020,35(5):302-327.
［9］ PALMIERI F.The mitochondrial transporter family SLC25:identification,properties and physiopathology［J］.Mol Aspects Med,2013,34(2-3):465-484.
［10］ ZIEGLER M,MONNE M,NIKIFOROV A,et al.Welcome to the family:Identification of the nad+transporter of animal mitochondria as member of the solute carrier family slc25［J］.Biomolecules,2021,11(6):880.
［11］ FIERMONTE G,PALMIERI L,DOLCE V,et al.The sequence,bacterial expression,and functional reconstitution of the rat mitochondrial dicarboxylate transporter cloned via distant homologs in yeast and caenorhabditis elegans［J］.J Biol Chem,1998,273(38):24754-24759.
［12］ RUPRECHT JJ,KUNJI ERS.The slc25 mitochondrial carrier family:Structure and mechanism［J］.Trends Biochem Sci,2020,45(3):244-258.
［13］ LASH LH.Mitochondrial GSH transport and intestinal cell injury:a commentary on "Contribution of mitochondrial GSH transport to matrix GSH status and colonic epithelial cell apoptosis"［J］.Free Radic Biol Med,2008,44(5):765-767.
［14］ JANG S,CHAPA-DUBOCQ XR,TYURINA YY,et al.Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes［J］.Redox Biol,2021,45:102021.
［15］ GRIFFITH OW,MEISTER A.Origin and turnover of mitochondrial glutathione［J］.Proc Natl Acad Sci U S A,1985,82(14):4668-4672.
［16］ LASH LH.Mitochondrial glutathione transport:physiological,pathological and toxicological implications［J］.Chem Biol Interact,2006,163(1-2):54-67.
［17］ KWON DH,LEE H,PARK C,et al.Glutathione induced immune-stimulatory activity by promoting m1-like macrophages polarization via potential ros scavenging capacity［J］.Antioxidants,2019;8(9):413.
［18］ LIU RM,GASTON PRAVIA KA.Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis［J］.Free Radic Biol Med,2010,48(1):1-15.
［19］ TRAGNI V,PRIMIANO G,TUMMOLO A,et al.Personalized medicine in mitochondrial health and disease:Molecular basis of therapeutic approaches based on nutritional supplements and their analogs［J］.Molecules,2022,27(11):3494.
［20］ ZHOU X,PAREDES JA,KRISHNAN S,et al.The mitochondrial carrier SLC25A10 regulates cancer cell growth［J］.Oncotarget,2015,6:(11)9271-9283.
［21］ ZHAO Q,ZHOU X,CURBO S et al.Metformin downregulates the mitochondrial carrier SLC25A10 in a glucose dependent manner［J］.Biochem Pharmacol,2018,156:444-450.
［22］ NOORIAN S,MOHAMMADPOOR NAMI S,NOURI GHONBALANI Z,et al.Compound heterozygous mutations presented with quadriparesis and menopause.A case report［J］.Twin Res Hum Genet,2022,25(2):74-76.
［23］ NGUYEN TT,QUAN X,HWANG KH,et al.Mitochondrial oxidative stress mediates high-phosphate-induced secretory defects and apoptosis in insulin-secreting cells［J］.Am J Physiol Endocrinol Metab,2015,308(11):e933-941.
［24］ HLOUSCHEK J,RITTER V,WIRSDORFER F,et al.Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia［J］.Cancer Lett,2018,439:24-38.
［25］ MONTERO J,MORALES A,LLACUNA L,et al.Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma［J］.Cancer Res,2008,68(13):5246-5256.
［26］ BAULIES A,MONTERO J,MATIAS N,et al.The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading［J］.Redox Biol,2018,14:164-177.
［27］ AN YA,CHEN S,DENG Y,et al.The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis［J］.J Hepatol,2021,75(2):387-399.
［28］ ZHOU Y,YANG C,WANG K，et al.MicroRNA-33b inhibits the proliferation and migration of osteosarcoma cells via targeting hypoxia-inducible factor-1α［J］.Oncol Res,2017,25(3):397-405.
［29］ WARNATZ HJ,SCHMIDT D,MANKE T,et al.The BTB and CNC homology 1 (BACH1) target genes are involved in the oxidative stress response and in control of the cell cycle［J］.J Biol Chem,2011,286(26):23521-23532.
［30］ WIEL C,LE GAL K,IBRAHIM MX,et al.BACH1 stabilization by antioxidants stimulates lung cancer metastasis［J］.Cell,2019,178(2):330-345.e22.
［31］ SELIM MS,KASSEM AB,EL-BASSIOUNY NA,et al.Polymorphic renal transporters and cisplatin' s toxicity in urinary bladder cancer patients:current perspectives and future directions［J］.Med Oncol,2023,40(2):80.
［32］ WANG B,CAO C,LIU X,et al.BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway［J］.Cell Oncol (Dordr),2020,43(2):223-235.
［33］ MORTAZAVI M,MOOSAVI F,MARTINI M,et al.Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer［J］.Crit Rev Oncol Hematol,2022,39(6):1-16.
［34］ LIU X,ZHAO P,WANG X,et al.Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells［J］.J Exp Clin Cancer Res,2019,38(1):184.
［35］ LI W,HU S,TIAN C,et al.TRIP4 transcriptionally activates DDIT4 and subsequent mTOR signaling to promote glioma progression［J］.Free Radic Biol Med,2021,177:31-47.
［36］ GOUBERT E,MIRCHEVA Y,LASORSA FM,et al.Inhibition of the mitochondrial glutamate carrier SLC25A22 in astrocytes leads to intracellular glutamate accumulation［J］.Front Cell Neurosci,2017,11:149.
［37］ WIRSCHING HG,WELLER M.The role of molecular diagnostics in the management of patients with gliomas［J］.Curr Treat Options Oncol,2016,17(10):51.
［38］ MOTAMEDIAN E,GHAVAMI G,SARDARI S.Investigation on metabolism of cisplatin resistant ovarian cancer using a genome scale metabolic model and microarray data［J］.Iran J Basic Med Sci,2015,18(3):267-276.
［39］ EATON BR,SCHWARZ R,VATNER R,et al.Osteosarcoma［J］.Pediatr Blood Cancer,2021,68(suppl_2):e28352.
［40］ GILL J,GORLICK R.Advancing therapy for osteosarcoma［J］.Nat Rev Clin Oncol,2021,18(10):609-624.
［41］ CHEN C,XIE L,REN T,et al.Immunotherapy for osteosarcoma:Fundamental mechanism,rationale,and recent breakthroughs［J］.Cancer Lett,2021,500:1-10.
［42］ WANG G,XIA J,CHEN C,et al.SLC25A10 performs an oncogenic role in human osteosarcoma［J］.Oncol Lett,2020,20(4):2.
［43］ TANG Z,FANG Y,DU R.MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer［J］.Biochem Biophys Res Commun,2019,512:331-337.
［44］ NEHA R,UMESH G,PROBHONJON B,et al.A pan-cancer metabolic atlas of the tumor microenvironment［J］.Cell Reports,2022,39(6):1-16.